518 related articles for article (PubMed ID: 24891321)
1. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.
Rajasagi M; Shukla SA; Fritsch EF; Keskin DB; DeLuca D; Carmona E; Zhang W; Sougnez C; Cibulskis K; Sidney J; Stevenson K; Ritz J; Neuberg D; Brusic V; Gabriel S; Lander ES; Getz G; Hacohen N; Wu CJ
Blood; 2014 Jul; 124(3):453-62. PubMed ID: 24891321
[TBL] [Abstract][Full Text] [Related]
2. Exploiting B-cell Receptor Stereotypy to Design Tailored Immunotherapy in Chronic Lymphocytic Leukemia.
Rovida A; Maccalli C; Scarfò L; Dellabona P; Stamatopoulos K; Ghia P
Clin Cancer Res; 2021 Feb; 27(3):729-739. PubMed ID: 33051305
[TBL] [Abstract][Full Text] [Related]
3. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
4. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).
Kowalewski DJ; Schuster H; Backert L; Berlin C; Kahn S; Kanz L; Salih HR; Rammensee HG; Stevanovic S; Stickel JS
Proc Natl Acad Sci U S A; 2015 Jan; 112(2):E166-75. PubMed ID: 25548167
[TBL] [Abstract][Full Text] [Related]
5. Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer.
Karasaki T; Nagayama K; Kawashima M; Hiyama N; Murayama T; Kuwano H; Nitadori J; Anraku M; Sato M; Miyai M; Hosoi A; Matsushita H; Kikugawa S; Matoba R; Ohara O; Kakimi K; Nakajima J
J Thorac Oncol; 2016 Mar; 11(3):324-33. PubMed ID: 26752676
[TBL] [Abstract][Full Text] [Related]
6. Identification of HLA-A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies.
Siegel S; Wagner A; Friedrichs B; Wendeler A; Wendel L; Kabelitz D; Steinmann J; Barsoum A; Coggin J; Rohrer J; Dreger P; Schmitz N; Zeis M
J Immunol; 2006 Jun; 176(11):6935-44. PubMed ID: 16709854
[TBL] [Abstract][Full Text] [Related]
7. A census of predicted mutational epitopes suitable for immunologic cancer control.
Warren RL; Holt RA
Hum Immunol; 2010 Mar; 71(3):245-54. PubMed ID: 20035814
[TBL] [Abstract][Full Text] [Related]
8. Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer.
Dao T; Klatt MG; Korontsvit T; Mun SS; Guzman S; Mattar M; Zivanovic O; Kyi CK; Socci ND; O'Cearbhaill RE; Scheinberg DA
Cancer Immunol Immunother; 2021 May; 70(5):1189-1202. PubMed ID: 33123756
[TBL] [Abstract][Full Text] [Related]
9. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes.
Mayr C; Bund D; Schlee M; Moosmann A; Kofler DM; Hallek M; Wendtner CM
Blood; 2005 Feb; 105(4):1566-73. PubMed ID: 15471955
[TBL] [Abstract][Full Text] [Related]
10. A polyvalent cellular vaccine induces T-cell responses against specific self-antigens overexpressed in chronic lymphocytic B-cell leukemia.
Kronenberger K; Nössner E; Frankenberger B; Wahl U; Dreyling M; Hallek M; Mocikat R
J Immunother; 2008 Oct; 31(8):723-30. PubMed ID: 18779747
[TBL] [Abstract][Full Text] [Related]
11. Neoantigens as potential vaccines in hepatocellular carcinoma.
Repáraz D; Ruiz M; Llopiz D; Silva L; Vercher E; Aparicio B; Egea J; Tamayo-Uria I; Hervás-Stubbs S; García-Balduz J; Castro C; Iñarrairaegui M; Tagliamonte M; Mauriello A; Cavalluzzo B; Buonaguro L; Rohrer C; Heim K; Tauber C; Hofmann M; Thimme R; Sangro B; Sarobe P
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193931
[TBL] [Abstract][Full Text] [Related]
12. An immunogenic personal neoantigen vaccine for patients with melanoma.
Ott PA; Hu Z; Keskin DB; Shukla SA; Sun J; Bozym DJ; Zhang W; Luoma A; Giobbie-Hurder A; Peter L; Chen C; Olive O; Carter TA; Li S; Lieb DJ; Eisenhaure T; Gjini E; Stevens J; Lane WJ; Javeri I; Nellaiappan K; Salazar AM; Daley H; Seaman M; Buchbinder EI; Yoon CH; Harden M; Lennon N; Gabriel S; Rodig SJ; Barouch DH; Aster JC; Getz G; Wucherpfennig K; Neuberg D; Ritz J; Lander ES; Fritsch EF; Hacohen N; Wu CJ
Nature; 2017 Jul; 547(7662):217-221. PubMed ID: 28678778
[TBL] [Abstract][Full Text] [Related]
13. Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing.
Karasaki T; Nagayama K; Kuwano H; Nitadori JI; Sato M; Anraku M; Hosoi A; Matsushita H; Takazawa M; Ohara O; Nakajima J; Kakimi K
Cancer Sci; 2017 Feb; 108(2):170-177. PubMed ID: 27960040
[TBL] [Abstract][Full Text] [Related]
14. Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes.
Weng J; Cha SC; Matsueda S; Alatrash G; Popescu MS; Yi Q; Molldrem JJ; Wang M; Neelapu SS; Kwak LW
Clin Cancer Res; 2011 Sep; 17(18):5945-52. PubMed ID: 21813633
[TBL] [Abstract][Full Text] [Related]
15. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.
Bilich T; Nelde A; Bichmann L; Roerden M; Salih HR; Kowalewski DJ; Schuster H; Tsou CC; Marcu A; Neidert MC; Lübke M; Rieth J; Schemionek M; Brümmendorf TH; Vucinic V; Niederwieser D; Bauer J; Märklin M; Peper JK; Klein R; Kohlbacher O; Kanz L; Rammensee HG; Stevanović S; Walz JS
Blood; 2019 Feb; 133(6):550-565. PubMed ID: 30530751
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations.
Hansen UK; Ramskov S; Bjerregaard AM; Borch A; Andersen R; Draghi A; Donia M; Bentzen AK; Marquard AM; Szallasi Z; Eklund AC; Svane IM; Hadrup SR
Front Immunol; 2020; 11():373. PubMed ID: 32226429
[TBL] [Abstract][Full Text] [Related]
17. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
[TBL] [Abstract][Full Text] [Related]
18. A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients.
Gallou C; Rougeot A; Graff-Dubois S; Kosmatopoulos K; Menez-Jamet J
Oncotarget; 2016 Sep; 7(37):59417-59428. PubMed ID: 27506946
[TBL] [Abstract][Full Text] [Related]
19. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
20. Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate.
Goddard RV; Prentice AG; Copplestone JA; Kaminski ER
Clin Exp Immunol; 2001 Oct; 126(1):16-28. PubMed ID: 11678895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]